Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing ...

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

In our news wrap Thursday, a group of states is suing the Trump administration over its planned 15% global tariff, Defense Secretary Pete Hegseth told Latin American countries to step up their fight ...

Day One Biopharmaceuticals stock remains a "Strong Buy." Learn more about its outlook, surging revenue, and ADC pipeline catalysts.

A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and expand use of its popular obesity shot.